Komori
Financial results presentation7733OLYMPUS CORPORATIONElectrical Equipment and Precision Instruments

Reference Materials for the Fiscal Year Ending March 2026 Financial Results

For the fiscal year ended March 2026, consolidated net sales increased year on year, while operating profit declined from ¥162.462 billion to ¥97.120 billion and net income declined from ¥117.855 billion to ¥68.172 billion. For the fiscal year ending March 2027, the company provided earnings forecasts including net sales of ¥1,055.0–1,076.0 billion and operating profit of ¥136.5–155.5 billion.

Worth reading
85Important
Scored from 3 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
65342
JPY million (year-on-year decrease in operating profit)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportFiscal year ending March 2026, full year6 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥1,010,676 million
Operating profit¥97,120 million
Ordinary income¥93,994 million profit before tax
Net income¥68,172 million
Selling, general and administrative expenses¥507,080 million
Gross Profit Margin
Rate64.7%
Operating profit margin
Rate9.6%
Results for the three months of the current quarter
Net Sales
¥295,281 million
Operating profit
¥26,867 million
Income before taxes
¥27,076 million
Net income
¥24,815 million
Full-year earnings forecast
Net Sales¥1,055,000–1,076,000 million
Operating profit¥136,500–155,500 million
Adjusted operating profit¥160,500–179,500 million
Income before taxes¥130,500–149,500 million
Net income¥95,500–109,000 million
Depreciation and amortization¥68,000 million
Capital Expenditures¥95,000 million
Research and development expenditure¥119,000 million
What the company explained in this material
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
JPY/USD¥155.00
JPY/EUR¥181.00/EUR
JPY/CNY¥22.50/CNY
New initiatives
  • Reorganization of the endoscopy and therapeutic devices businesses into GIS and SIS
  • Allocation of part of corporate expenses to GIS and SIS
Key KPIsA metric the company considers important as a management benchmark.
  • Average yen/USD exchange rate during the period¥150.77
  • Average yen/EUR exchange rate during the period¥174.79
  • Average yen/CNY exchange rate during the period¥21.25
  • Impact of foreign exchange rates on net sales¥13,560 million
  • Impact of foreign exchange rates on operating profit¥-339 million
  • Equity ratio52.8%
Segment results
  • GIS
    Net Sales¥697,359 million
    Operating profit¥136,359 million
    Year-on-year change in revenue3.5%
    Year-on-year operating profit growth-20.5%
  • SIS
    Net Sales¥313,109 million
    Operating loss¥14,986 million operating loss
    Year-on-year change in revenue-3.0%
  • Medical Field
    Net Sales¥1,010,468 million
    Operating profit¥121,373 million
    Year-on-year change in revenue1.4%
    Year-on-year operating profit growth-35.0%
  • Corporate eliminations
    Operating loss¥23,754 million operating loss
Number of employees
Number of Employees28,138 employees (including 17,059 overseas employees)
Change during the periodDecreased from 29,297 at the end of March 2025
Capital expenditures
95,000 Millions of yen FY2027 guidance
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings report
Fiscal Period CoveredFiscal year ending March 2026, full year
Net Sales¥1,010,676 million
Operating profit¥97,120 million
Ordinary income¥93,994 million (profit before tax)
Net income¥68,172 million
Gross Profit MarginRate 64.7% / Year-on-year change (points) Not disclosed
Operating profit marginRate 9.6% / Year-on-year change (points) Not disclosed
Selling, general and administrative expenses¥507,080 million
Results for the three months of the current quarterNet Sales ¥295,281 million / Operating profit ¥26,867 million / Income before taxes ¥27,076 million / Net income ¥24,815 million
Full-year earnings forecastNet Sales ¥1,055,000–1,076,000 million / Operating profit ¥136,500–155,500 million / Adjusted operating profit ¥160,500–179,500 million / Income before taxes ¥130,500–149,500 million / Net income ¥95,500–109,000 million / Depreciation and amortization ¥68,000 million / Capital Expenditures ¥95,000 million / Research and development expenditure ¥119,000 million
Segment resultsSegment GIS / Net Sales ¥697,359 million / Operating profit ¥136,359 million / Year-on-year change in revenue 3.5% / Year-on-year operating profit growth -20.5%, Segment SIS / Net Sales ¥313,109 million / Operating loss ¥14,986 million operating loss / Year-on-year change in revenue -3.0% / Year-on-year operating profit growth Not disclosed, Segment Medical Field / Net Sales ¥1,010,468 million / Operating profit ¥121,373 million / Year-on-year change in revenue 1.4% / Year-on-year operating profit growth -35.0%, Segment Corporate eliminations / Operating loss ¥23,754 million operating loss
Key KPIsIndicator name Average yen/USD exchange rate during the period / Value ¥150.77 / Year on year against the same period last year Not disclosed, Indicator name Average yen/EUR exchange rate during the period / Value ¥174.79 / Year on year against the same period last year Not disclosed, Indicator name Average yen/CNY exchange rate during the period / Value ¥21.25 / Year on year against the same period last year Not disclosed, Indicator name Impact of foreign exchange rates on net sales / Value ¥13,560 million / Year on year against the same period last year Not disclosed, Indicator name Impact of foreign exchange rates on operating profit / Value ¥-339 million / Year on year against the same period last year Not disclosed, Indicator name Equity ratio / Value 52.8% / Year on year against the same period last year Not disclosed
Number of employeesNumber of Employees 28,138 employees (including 17,059 overseas employees) / Change during the period Decreased from 29,297 at the end of March 2025
Assumptions Underlying the Business OutlookJPY/USD ¥155.00 / JPY/EUR ¥181.00/EUR / JPY/CNY ¥22.50/CNY
Capital expenditures95,000 Millions of yen (FY2027 guidance)
New initiativesReorganization of the endoscopy and therapeutic devices businesses into GIS and SIS, Allocation of part of corporate expenses to GIS and SIS
Items this document does not state (14)
Progress against full-year forecastSelf-assessment against the planBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No reasons for the changes in consolidated results have been provided. In addition, the business and reporting segments were reorganized into GIS and SIS from the fiscal year ended March 2026, and part of corporate expenses was allocated to both segments. Segment figures for prior fiscal years have therefore been reclassified.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Reference Materials for the Fiscal Year Ending March 2026 Financial Results | OLYMPUS CORPORATION (7733) timely disclosure | Komori